Apixaban versus enoxaparin for venous thromboembolism prophylaxis after total gastrectomy in patients with gastric cancer: a randomized controlled trial

Apixaban demonstrated similar adherence, as measured by PDC, to enoxaparin, with no safety concerns identified in this pilot study. It also demonstrated greater patient satisfaction. While these results suggest apixaban might be a more patient-friendly alternative for postoperative VTE prophylaxis in gastric cancer patients undergoing total gastrectomy, larger studies are warranted to confirm its safety and efficacy as their primary outcome.